A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)
Clinical trial NCT05669014 · COMPLETED
Trial details
- NCT number
- NCT05669014
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-04
- Primary completion
- 2025-07-02
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.